SCHEMBL6809754

SCHEMBL6809754

COc1ccc2c(O)cc(-c3cccc(C)n3)nc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.46
ALDH1A1 P00352 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
CCR1 P32246 1/20 0.43
CCR8 P51685 1/20 0.43
TGFBR1 P36897 3/20 0.43
NPSR1 Q6W5P4 1/20 0.42
TLR8 Q9NR97 1/20 0.41
MPO P05164 1/20 0.41
TACR3 P29371 4/20 0.40
ACP1 P24666 1/20 0.40
MEN1 O00255 2/20 0.40
POLB P06746 2/20 0.40
KMT2A Q03164 2/20 0.40
NPC1 O15118 1/20 0.40
LMNA P02545 1/20 0.40
NQO2 P16083 1/20 0.40
RAB9A P51151 1/20 0.40
MAPK14 Q16539 1/20 0.39
GRM5 P41594 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1088686 0.83 CCR1 (0.48) KDM4EALDH1A1CCR1CCR8TGFBR1
SCHEMBL8139843 0.83 ACP1 (0.43) KDM4EALDH1A1SMN1; SMN2NPSR1TLR8
SCHEMBL1536729 0.81 CYP3A4 (0.51) KDM4EALDH1A1SMN1; SMN2NPSR1TLR8
SCHEMBL8139912 0.79 NPSR1 (0.54) KDM4EALDH1A1SMN1; SMN2NPSR1TLR8
SCHEMBL8135614 0.79 TLR8 (0.45) KDM4EALDH1A1SMN1; SMN2CCR1CCR8
SCHEMBL743975 0.79 KDM4E (0.72) KDM4EALDH1A1SMN1; SMN2NPSR1TACR3
SCHEMBL12732312 0.79 KDM4E (0.58) KDM4EALDH1A1SMN1; SMN2NPSR1TACR3
SCHEMBL6809626 0.78 ALDH1A1 (0.45) KDM4EALDH1A1SMN1; SMN2TLR8MPO
SCHEMBL996497 0.77 CCR1 (0.42) CCR1CCR8TGFBR1MEN1KMT2A
SCHEMBL21083327 0.77 TGFBR1 (0.51) ALDH1A1SMN1; SMN2CCR1CCR8TGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1169339-B1 MACROCYCLIC PEPTIDES INHIBITING THE HEPATITIS C VIRUS NS3 PROTEASE BOEHRINGER INGELHEIM CA LTD (CA) 2004-09-29 EP disclosed
EP-1437362-A1 Macrocyclic peptides inhibiting the hepatitis C virus ns3 protease BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2004-07-14 EP disclosed
US-20040002448-A1 Macrocyclic peptides active against the hepatitis C virus BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2004-01-01 US disclosed
US-6608027-B1 Macrocyclic small peptides of low molecular weight that are inhibitory to NS3 protease of hepatitis C virus BOEHRINGER INGELHEIM (CANADA) LTD (CA) 2003-08-19 US disclosed
EP-1169339-A1 MACROCYCLIC PEPTIDES INHIBITING THE HEPATITIS C VIRUS NS3 PROTEASE BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2002-01-09 EP disclosed
WO-2000059929-A1 MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2000-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002448-A1 Macrocyclic peptides active against the hepatitis C virus VIP, FURIN, RNASE1 KDM4E 3584/4885ALDH1A1 1770/4885SMN1; SMN2 2976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.